Idiopathic Hypersomnia Treatment Market, by Drug Class (Stimulant Medications, Non-stimulant wake-promoting Medications, and Sodium Oxybate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020

Code : CMI4306

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

No regulatory approved product
Side effect of current off-label drugs

Global Idiopathic Hypersomnia Treatment Market - Restraint

Side effects of current off-label drugs for hypersomnia which include aggressive behavior & dependence and no approved product are some of the major factors that are expected to hinder growth of the global idiopathic hypersomnia treatment market. Moreover, declining less patient pool for clinical trials is also a major setback for the global idiopathic hypersomnia treatment market, which is expected to hamper growth of the market.

Increase in lifestyle diseases such as anxiety, depression, and increasing diagnosis rate of hypersomnia are expected to drive the market growth over the forecast period

Growing incidence of lifestyle diseases such as anxiety, depression, etc. caused by behavioral changes, social activities, which affects the sleep cycle is the major factor responsible for growth of the global idiopathic hypersomnia treatment market. These changes lead to anxiety, depression, & other health issues, in which patients feel tired during the daytime and are more prone to hypersomnia. For instance, according to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the U.S. of age 18 and older, or 18.1% of the population every year.

Furthermore, increasing diagnosis rate of hypersomnia coupled with technological advancements for diagnosis of hypersomnia are expected to fuel growth of the global idiopathic hypersomnia treatment market. For instance, multiple sleep latency test (MSLT) is the standard tool used to diagnose narcolepsy and idiopathic hypersomnia, which is offered at AASM-accredited sleep centers in the U.S.

Increasing number of pipeline products is expected to drive the market growth over the forecast period

Rising number of pipeline products for idiopathic hypersomnia treatment is also a major factor that is expected to boost growth of the global idiopathic hypersomnia treatment market. For instance, in January 2020, Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company Limited initiated the phase1 study of a single intravenous infusion dose of TAK-925 in participants with idiopathic hypersomnia.